Janssen/Legend Plan Phased US Launch For BCMA-Targeting CAR-T Carvykti

First Multiple Myeloma Patient Could Be Infused In Six Weeks

 
• By Mandy Jackson

Janssen priced the one-time autologous treatment at $465,000, well above the $419,500 list price for Bristol’s first-to-market CAR-T, but expects broad commercial and Medicare coverage. 

Red balloon mid air amongst wooden square cubes
A phased launch will allow for careful certification of treatment centers • Source: Alamy

More from New Products

More from Scrip